Magnevist (Gadopentetate Dimeglumine)

Gadopentetate dimeglumine contains a gadolinium ion chelated to a stable organic molecule. After injection, the complex distributes in the extracellular space and shortens the T1 relaxation time of nearby water protons, leading to increased signal intensity on T1‑weighted MRI images and enhanced contrast between normal and abnormal tissues.

The dose of Magnevist is determined by the prescribing physician based on the patient’s weight, the type of MRI study, and renal function. The healthcare professional calculates the appropriate volume of the 0.5 mmol/mL solution to achieve the required contrast effect.

Safety of Magnevist in pregnancy and lactation has not been fully established. It should be used only if the diagnostic benefit outweighs the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Magnevist, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Magnevist is a linear, non‑ionic gadolinium‑based agent with a well‑characterized safety profile. Compared with macrocyclic agents, it has a similar efficacy for enhancing T1‑weighted images but may carry a slightly higher theoretical risk of nephrogenic systemic fibrosis in patients with severe renal impairment. Choice of agent depends on clinical context and patient risk factors.

Magnevist should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product or shake the vial vigorously. Keep the solution in its original packaging until use to maintain stability and sterility.

Magnevist is administered as an injection solution, typically delivered intravenously by a trained healthcare professional. The volume is injected rapidly, often followed by a saline flush, and the timing of the MRI scan is coordinated to capture the period of maximal tissue enhancement.

The most serious risks include severe allergic reactions such as anaphylaxis and nephrogenic systemic fibrosis (NSF), a rare but serious fibrotic condition that can occur in patients with severe renal dysfunction. Prompt recognition and management of these reactions are essential.

Magnevist should be avoided in patients with known hypersensitivity to gadopentetate dimeglumine or any component of the formulation, and in those with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of NSF. Caution is also advised for pregnant or breastfeeding women unless clearly indicated.